Author: healthadmin

During their quarterly conference call, Legend Biotech executives expressed little concern about new threats to the company’s only commercial product, the multiple myeloma CAR-T Carvykti. Oddly enough, this competition is being conducted through Karvicti’s commercial partner, Johnson & Johnson. Over the past three months, the pharmaceutical giant has announced data from two successful trials of its multiple myeloma bispecific Tecvayli. One in combination with J&J’s Darzalex and the other with BCMAxCD3 T-cell engager as a single agent. The results of the study show a competitive profile compared to Carvykti, and the combo quickly won FDA approval last week. During Tuesday’s…

Young people with depression exhibit abnormal cellular energy patterns in both the brain and blood, characterized by overactive cells at rest, but unable to respond appropriately to physical stress. This biological manifestation of fatigue suggests that early medical intervention may help restore cellular balance before long-term physical damage occurs. The study was published in the journal translational psychiatry. Fatigue is a common and disabling symptom of major depressive disorder. Despite the prevalence of this severe fatigue, its biological origins remain largely a mystery. Medical professionals need a clearer picture of how depression changes the body at a microscopic level to…

Researchers have developed a capsule-based method that allows them to analyze the same cells through multiple experimental steps. This technology could overcome long-standing limitations in cell research and open new ways to study disease mechanisms at the single-cell level. In a study published in a scientific journal scienceVisiting Professor Linas Mazutis and his research team at Umeå University have presented a new technique for analyzing individual cells. This method addresses long-standing technical challenges in cell research. Until now, scientists have typically been able to analyze each cell only once, making it difficult to study how individual cells change or respond…

The Trump administration’s campaign to make America’s soil healthy again has a dirty side. At times, the plan sounds like it was written by Democrats. Groups that cheered the Biden administration’s climate-smart agriculture efforts are hearing familiar echoes in the USDA’s new regenerative agriculture pilot program that pays farmers to choose from a list of Washington-approved conservation practices. Just a few years ago, Republicans might have balked at the concept and resisted teaching farmers how to farm. It’s now a pillar of the Republican administration’s “Make America Healthy Again” policy, which argues that healthier soils and less pesticide use will…

Recent research published in journals addictive behavior Evidence shows that almost one in five people who seek help for a gambling problem experience suicidal thoughts. This study suggests that factors such as overwhelming debt and lack of social support increase this risk for both men and women. These findings highlight the serious mental health consequences of gambling addiction and point to the need for stronger prevention and support systems. The researchers wanted to identify specific mechanisms that contribute to gambling-related suicides in both genders. Past evidence suggests that the relationship between gambling and suicidal ideation is highly complex. It is…

While much of the company’s recent focus remains on strengthening U.S. infrastructure, Eli Lilly has moved for the second time this week to increase drug manufacturing capacity overseas, and again in Asia. The company announced Thursday a 20 billion yen (approximately $126 million) expansion of its Seishin factory in Kobe. Lilly’s local unit plans to install a new production line there and add a new warehouse by 2028, according to a Japanese press release (PDF). Lilly did not say which medicines the expansion would support, but Nikkei Asia reported on March 12 that the project would boost manufacturing of drugs…

The FDA is retiring the old and introducing a new one, announcing a new adverse event surveillance system that combines multiple reporting systems into one integrated platform. The initiative is expected to save approximately $120 million over the next five years. The program, called the FDA Adverse Event Monitoring System (AEMS), is consistent with FDA’s mission to “modernize the safety of regulated products and provide radical transparency,” the agency said in a March 11 press release. FDA Commissioner Marty McCurry, M.D., said the current adverse event reporting system is “outdated and fragmented,” wasting “millions of taxpayer dollars” and creating blind…

Marama Health, a doula-led, Medicaid-focused maternal and child care provider, has closed a $9.2 million seed round. The oversubscribed round was led by Acumen America, a VC firm focused on health and economic justice, with participation from Wisdom Ventures, Capital F, Coyote Ventures, and angel investors. This includes a $2.3 million National Institutes of Health (NIH) grant and more than $1 million in California funding. Marama will use the funding to expand into more Medicaid markets, expand its doula workforce, and deepen its partnerships with community health centers. The NIH grant will be used to study how women with high-risk…

According to the Alzheimer’s Association, an estimated 7.2 million Americans over the age of 65 have Alzheimer’s disease. Current diagnostic tests typically measure the levels of two proteins in the blood or spinal fluid: amyloid beta (Aβ) and phosphorylated tau (p-tau). Although these biomarkers are widely used, they may not fully reflect the earliest biological changes that occur during disease progression. Researchers at Scripps Research have now introduced a different type of blood test that focuses on how proteins are folded in the bloodstream, rather than how much is present. Their findings are: natural aging February 27, 2026 Researchers have…

It’s hard to say exactly what the future holds for mass compounding of GLP-1, but pressure is mounting from a variety of angles in the U.S., with drug companies and the FDA alike trying to crack down on the practice. Eli Lilly, currently engaged in multiple efforts in court to protect its diabetes and obesity treatments Maunjaro and Zepbound from pharmacists, medical spas and telemedicine companies, is launching a new salvo focused on the potential safety risks behind common compounding tactics. Lilly warned on Thursday that its own testing had “discovered significant levels of impurities” in certain compounded products sold…